Company presentations entries 2026

Arphamid develops therapeutics that keep cancer patients on life-saving treatment. We target debilitating complications that force patients to reduce or stop chemotherapy. Dimiracetam, a glutamate modulator (Phase 2-ready), prevents early symptoms of oxaliplatin neuropathy. RF4662 reduces breakthrough pain episodes via GPR103 antagonism (IND-ready). RF4442 addresses cachexia via GPR10 antagonism. We seek €25M to advance three value-inflection milestones toward a €3.5B market.

Tuesday, May 5, 13:45 - 15:00, room Singapore

Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on developing and commercializing innovative medicines for rare neuromuscular diseases with high unmet medical need. Santhera holds an exclusive worldwide license from ReveraGen to AGAMREE® (vamorolone), a dissociative steroid investigated in DMD as an alternative to corticosteroids. AGAMREE is approved for DMD in the U.S., EU, UK, China, Hong Kong, and Canada.

Ultimate Medicine (UM) is a Swiss preclinical biotech focused on maximizing the healthspan of patients with Alzheimer's disease and other dementias. The company is pioneering a class of small molecules targeting elevated levels of a novel toxic metabolite that disrupts critical neuronal functions and accelerates disease progression. The company’s lead program is an oral small-molecule inhibitor designed to block metabolite synthesis.

Monday, May 4, 16:00 - 16:15, room Singapore